Chronic Lymphocytic Leukemia
Alemtuzumab effective therapy for CLL with p53 mutations and deletions
Published in Hematology Week, August 2nd, 2004
"The presence of p53 mutation or deletion predicts for poor response to conventional therapy in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti-CD52 antibody alemtuzumab was effective in this patient group.
"Thirty-six patients with fludarabine-refractory CLL were treated with alemtuzumab, 15 (42%) of whom had p53 mutations or deletions," researchers in the United States report.
"Clinical responses in patients with p53 mutations, deletions, or both were noted in 6 (40%) of 15 versus 4 (19%)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2004-08-02)
More Articles from Hematology Week
- Graft Versus Host Disease
DC stimulation of donor CD8+ T cells may be useful for prevention of GVHD - Pharmacogenetics
Pharmacogenetics can improve identification of high-risk ALL patients - Stem Cell Transplantation
Primary systemic amyloidosis patients have increased survival following PBSCT - Tumor Suppression
p300 and CBP are suppressors of hematological tumor formation - Acute Lymphoblastic Leukemia
Novel FLT3 inhibitors may be considered to treat hyperdiploid or relapsed ALL - Acute Myeloid Leukemia
FLT3 mutations in AML adversely associate with CR with intensive chemotherapy - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
